Sorrento Therapeutics, Inc. announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including methicillin-resistant S. aureus, was renewed for the second year of a two year Phase I grant award.
[More]
Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.
[More]
RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for the development of RYI-008 in China.
[More]
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
[More]
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.
[More]
CMC Biologics today announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody.
[More]
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein.
[More]
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system - a network of vessels that transports and stores immune cells throughout the body - to promote the spread of disease, a process called metastasis.
[More]
Novartis announced today that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.
[More]
Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.
[More]
Harvard School of Public Health (HSPH) researchers have discovered that a particular type of protein (hormone) found in fat cells helps regulate how glucose (blood sugar) is controlled and metabolized (used for energy) in the liver.
[More]
Continuing analysis of an HIV vaccine trial undertaken in Thailand is yielding additional information about how immune responses were triggered and why the vaccine did not protect more people.
[More]
Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.
[More]
Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.
[More]
NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's.
[More]
A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment.
[More]
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
[More]
Regeneron Pharmaceuticals, Inc. today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi.
[More]
Emergent BioSolutions Inc. today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and Antibody Engineering Summit, currently underway in Boston, MA.
[More]